InterAct Therapeutics
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
InterAct Therapeutics is a biotech startup developing precision therapies to treat metastatic cancers by targeting the unique biology of organ-specific disease. Its lead program, IAT-S2, is designed for breast cancer–derived liver metastases (BCLM), a condition with fewer than 10% five-year survival and no disease-specific therapies. Rather than targeting tumor cells directly, the company’s approach focuses on reprogramming the liver microenvironment to resist metastatic colonization and progression. Preclinical studies demonstrate that modulating this environment can significantly reduce tumor burden without affecting primary tumor growth. The company’s platform, InterAct Print™, is a modality-agnostic discovery engine that identifies targets across metastatic sites and enables therapeutic development using AAV, siRNA, and LNP-mRNA approaches. By focusing on metastasis, the primary cause of cancer mortality, InterAct aims to build a scalable pipeline of organ-directed therapies.
Company HQ City:
Dallas
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2025
Lead Product in Development:
IAT-S2
CEO
Dan Hargrove, CEO
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Q2-Q3 2027
What is your next catalyst (value inflection) update?
Our next major value inflection is achieving IND readiness, driven by completion of IND-enabling activities including GLP toxicology in minipigs, GMP AAV manufacturing, and finalization of our clinical trial design following FDA INTERACT alignment. This milestone meaningfully de-risks the program across CMC, nonclinical, and regulatory dimensions and positions us to initiate our first-in-human Phase 1 study.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}